Compare Lupin with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs DIVIS LABORATORIES - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN DIVIS LABORATORIES LUPIN/
DIVIS LABORATORIES
 
P/E (TTM) x 46.9 57.6 81.6% View Chart
P/BV x 4.3 15.4 28.0% View Chart
Dividend Yield % 0.5 0.4 126.4%  

Financials

 LUPIN   DIVIS LABORATORIES
EQUITY SHARE DATA
    LUPIN
Mar-20
DIVIS LABORATORIES
Mar-19
LUPIN/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8821,639 53.8%   
Low Rs5051,115 45.3%   
Sales per share (Unadj.) Rs339.4186.3 182.2%  
Earnings per share (Unadj.) Rs-5.951.0 -11.7%  
Cash flow per share (Unadj.) Rs15.557.3 27.0%  
Dividends per share (Unadj.) Rs6.0016.00 37.5%  
Dividend yield (eoy) %0.91.2 74.5%  
Book value per share (Unadj.) Rs276.7261.8 105.7%  
Shares outstanding (eoy) m453.00265.47 170.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.07.4 27.6%   
Avg P/E ratio x-116.627.0 -431.6%  
P/CF ratio (eoy) x44.824.0 186.6%  
Price / Book Value ratio x2.55.3 47.6%  
Dividend payout %-100.931.4 -321.3%   
Avg Mkt Cap Rs m314,201365,592 85.9%   
No. of employees `00018.311.8 154.5%   
Total wages/salary Rs m29,8685,423 550.8%   
Avg. sales/employee Rs Th8,400.64,175.1 201.2%   
Avg. wages/employee Rs Th1,632.0457.7 356.5%   
Avg. net profit/employee Rs Th-147.21,141.8 -12.9%   
INCOME DATA
Net Sales Rs m153,74849,463 310.8%  
Other income Rs m4,8381,556 310.8%   
Total revenues Rs m158,58551,019 310.8%   
Gross profit Rs m24,84918,718 132.8%  
Depreciation Rs m9,7021,689 574.4%   
Interest Rs m3,63035 10,370.9%   
Profit before tax Rs m16,35518,551 88.2%   
Minority Interest Rs m40-   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,5715,023 230.3%   
Profit after tax Rs m-2,69413,527 -19.9%  
Gross profit margin %16.237.8 42.7%  
Effective tax rate %70.827.1 261.3%   
Net profit margin %-1.827.3 -6.4%  
BALANCE SHEET DATA
Current assets Rs m154,13246,501 331.5%   
Current liabilities Rs m92,2528,468 1,089.5%   
Net working cap to sales %40.276.9 52.3%  
Current ratio x1.75.5 30.4%  
Inventory Days Days82131 62.7%  
Debtors Days Days12986 150.6%  
Net fixed assets Rs m89,08225,797 345.3%   
Share capital Rs m906531 170.7%   
"Free" reserves Rs m124,46168,962 180.5%   
Net worth Rs m125,36769,493 180.4%   
Long term debt Rs m17,9330-   
Total assets Rs m249,83980,383 310.8%  
Interest coverage x5.5531.0 1.0%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.6 100.0%   
Return on assets %0.416.9 2.2%  
Return on equity %-2.119.5 -11.0%  
Return on capital %8.726.7 32.6%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m51,45041,238 124.8%   
Fx outflow Rs m19,47012,405 157.0%   
Net fx Rs m31,98028,833 110.9%   
CASH FLOW
From Operations Rs m14,6889,543 153.9%  
From Investments Rs m11,070-6,854 -161.5%  
From Financial Activity Rs m-8,906-2,459 362.1%  
Net Cashflow Rs m16,853230 7,339.9%  

Share Holding

Indian Promoters % 46.6 52.0 89.6%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 11.8 95.8%  
FIIs % 31.9 19.0 167.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 17.2 58.7%  
Shareholders   98,259 31,796 309.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ABBOTT INDIA  STRIDES PHARMA SCIENCE  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 7, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS